Molnupiravir + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease (COVID-19)
Conditions
Coronavirus Disease (COVID-19)
Trial Timeline
Oct 19, 2020 → May 5, 2022
NCT ID
NCT04575597About Molnupiravir + Placebo
Molnupiravir + Placebo is a phase 2/3 stage product being developed by Merck for Coronavirus Disease (COVID-19). The current trial status is completed. This product is registered under clinical trial identifier NCT04575597. Target conditions include Coronavirus Disease (COVID-19).
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06667700 | Phase 3 | Recruiting |
| NCT04939428 | Phase 3 | Completed |
| NCT04575597 | Phase 2/3 | Completed |
| NCT04575584 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Coronavirus Disease (COVID-19)